CONTINUED… Read this full press release and more news for Actinium Pharmaceuticals at: Other recent developments in the biotech industry of note include: Bristol Myers Squibb (NYSE: BMY) recently announced that the European Commission (EC) has granted approval to Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Radiotherapy is a complex process that involves understanding the principles of medical physics, dosimetry, radiotherapy planning radiobiology, delivery and interaction of radiation therapy with other treatment modalities and the radiation safety.” Active biotech and pharma companies in the markets this week include Actinium Pharmaceuticals, Inc.(NYSE AMERICAN: ATNM), Bristol Myers Squibb (NYSE: BMY), Eli Lilly and Company's (NYSE: LLY), Novartis AG (NYSE: NVS), AstraZeneca PLC (NASDAQ: AZN).
At the forefront, product, technology, and the application of radiotherapy analyzers serve as the cornerstones, facilitating consumables used in analysis.” Actinium Pharmaceuticals, Inc.(NYSE AMERICAN: ATNM) Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities – Actinium Pharmaceuticals, Inc.(Actinium or the Company), a pioneer in the development of targeted radiotherapies, recently announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler.
The story "Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements" has 1827 words across 60 sentences, which will take approximately 8 - 16 minutes for the average person to read.
Which news outlet covered this story?
The story "Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements" was covered 5 days ago by GlobeNewswire, a news publisher based in China.
How trustworthy is 'GlobeNewswire' news outlet?
GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.
The outlet is headquartered in China and publishes an average of 51 news stories per day.
It's most recent story was published 14 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
